bioRxiv : the preprint server for biology · 2020
Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray.
ПрепринтСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Assis Rafael R, Jain Aarti, Nakajima Rie, Jasinskas Algis, Felgner Jiin, Obiero Joshua M, Adenaiye Oluwasanmi, Tai Sheldon, Hong Filbert, Norris Philip J, Stone Mars, Simmons Graham, Bagri Anil, Schreiber Martin, Buser Andreas, Holbro Andreas, Battegay Manuel, Hosimer Philip, Noesen Charles, Milton Donald K, Prometheus Study Group, Davies D Huw, Contestable Paul, Corash Laurence M, Busch Michael P, Felgner Philip L, Khan Saahir
Аннотация
The current practice for diagnosis of COVID-19, based on SARS-CoV-2 PCR testing of pharyngeal or respiratory specimens in a symptomatic patient at high epidemiologic risk, likely underestimates the true prevalence of infection. Serologic methods can more accurately estimate the disease burden by detecting infections missed by the limited testing performed to date. Here, we describe the validation of a coronavirus antigen microarray containing immunologically significant antigens from SARS-CoV-2, in addition to SARS-CoV, MERS-CoV, common human coronavirus strains, and other common respiratory viruses. A comparison of antibody profiles detected on the array from control sera collected prior to the SARS-CoV-2 pandemic versus convalescent blood specimens from virologically confirmed COVID-19 cases demonstrates near complete discrimination of these two groups, with improved performance from use of antigen combinations that include both spike protein and nucleoprotein. This array can be used as a diagnostic tool, as an epidemiologic tool to more accurately estimate the disease burden of COVID-19, and as a research tool to correlate antibody responses with clinical outcomes.